740 results on '"Koomen, John M."'
Search Results
2. Mapping the cancer surface proteome in search of target antigens for immunotherapy
3. Implementation of a High-Accuracy Targeted Gene Expression Panel for Clinical Care
4. Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell MigrationSystems Analysis of AXL Signaling in Lung Cancers
5. HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis
6. Associations of gut microbiome with endogenous estrogen levels in healthy postmenopausal women
7. Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2
8. A metabolic perspective on nitric oxide function in melanoma
9. Targeted mass-spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP kinase, and AKT signaling
10. Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy
11. Brain metastasis-associated fibroblasts secrete fucosylated PVR/CD155 that induces breast cancer invasion
12. Macrophages use apoptotic cell-derived methionine and DNMT3A during efferocytosis to promote tissue resolution
13. Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer
14. Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma
15. Associations of established breast cancer risk factors with urinary estrogens in postmenopausal women
16. The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors
17. Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation
18. Does artificial intelligence need companionship to assist in drug discovery? The Kirsten rat sarcoma virus study
19. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
20. Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma
21. Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets
22. LC-HRMS of derivatized urinary estrogens and estrogen metabolites in postmenopausal women
23. Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells
24. Macrophage Metabolism of Apoptotic Cell-Derived Arginine Promotes Continual Efferocytosis and Resolution of Injury
25. Branched-chain keto acids promote an immune-suppressive and neurodegenerative microenvironment in leptomeningeal disease
26. Figure S7 Part 2 from CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma
27. Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2
28. Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets
29. Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach.
30. Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells
31. CK1δ/CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma
32. Managing a Large-Scale Multiomics Project: A Team Science Case Study in Proteogenomics
33. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas
34. Deciphering Phenotypes from Protein Biomarkers for Translational Research with PIPER
35. Abstract B015: Wildtype RAS activity and PI3K signaling as new vulnerabilities in cells with acquired resistance to sotorasib
36. Dose‐escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF ‐mutant solid tumors
37. Supplementary Figure from TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate
38. Data from TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate
39. Supplementary Table from TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate
40. Abstract 3839: Discovery of GSTZ1 as a novel target for drug refractory non-small cell lung cancer by using fragment-based chemical proteomics
41. Data from Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell Migration
42. Supplementary Figure S6 from PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
43. Supplementary Table from Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell Migration
44. Supplemental Methods and Legends from Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling
45. Supplementary Legends from Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer
46. Data from Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy–Mediated Metastatic Melanoma Phenotype
47. Supplementary Figures 1 - 5, Table 1 from Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma
48. Supplementary Materials and Methods from Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer
49. Supplementary Table S2 from PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
50. Data from Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.